Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 11:02:22 12/03/2026 GMT			5-day change	1st Jan Change
75.98 ^EUR	-0.35%		-2.24%	-8.14%

03-10	Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit	RE
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE

SANOFI : UBS keeps its Buy rating

Published on 10/03/2025 at 08:18 am BST

MarketScreener with dpa-AFX Analyser

SANOFI

-0.35%

Analyst Matthew Weston from UBS research considers the stock attractive and recommends it with a Buy rating. The target price is reduced from EUR 115 to EUR 105.

Latest news about Sanofi

03-10	Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit	RE
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE
03-09	Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study	RE
03-06	Brazil's EMS purchases Sanofi's Medley in deal worth over $500 million	RE
03-06	Brazil's EMS purchases Sanofi's Medley	RE
03-05	Merck Outlook Disappoints – MS Drug Patent Loss Weighs on Forecast	RE
03-05	Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee	CI
03-05	Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings	DJ
03-04	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
03-04	Euroapi
03-04	Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals	DJ
03-04	Sino Biopharm Unit Signs Global License Deal With Sanofi for Rovadicitinib	MT
03-04	Sino Biopharm Inks Up to $1.5 Billion Deal With Sanofi for Cancer Treatment	DJ
03-03	Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion	RE
03-03	Blackstone Gives Teva $400 Million to Develop Inflammatory Bowel Disease Treatment	DJ

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).

Employees

74,846

Sector

Pharmaceuticals

Calendar

04-23 - Earnings release - Q1 2026

More about the company